The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency

European Journal of Clinical Pharmacology

Volumn 55, Issue 4, 1999, Pages 269-277

  Gehr, T W B ^a,c   Tenero, D M ^b   Boyle, D A ^b   Qian, Y ^b   Sica, D A ^a   Shusterman, N H ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Box 980160 ^*  (United States)

Author keywords

Carvedilol; Hypertension; Renal insufficiency

Indexed keywords

CARVEDILOL; DRUG METABOLITE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; HYPERTENSION; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBAZOLES; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPANOLAMINES; SINGLE-BLIND METHOD; STEREOISOMERISM;

EID: 0032957957     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050628     Document Type: Article

References (17)

1. 1. Eggertsen R, Andren L, Sivertsson R, Hansson L (1984) Acute hemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary haemodynamic vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol 27: 19-22
2. 2. Meyer-Sabellek WA, Schulte K-L, Thiede HM, Gotzen R (1983) Acute hypotensive response to the new antihypertensive agent BM 14190 in essential hypertensive patients. J Hypertens 1[Suppl]: 351-352
3. 3. Packer M, Briston MR, Cohn JN, et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349-1355
4. 4. McTavis D, Campoli-Richards D, Sorkin EM (1997) Carvedilol: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy. Drugs 45: 232-258
5. 5. Neugebauer G, Akpan W, von Mollendorff E, Neubert P, Reiff K (1987) Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol [Suppl 11]: 585-588
6. 6. Boyle DU, Tenero DM, Cyronak MJ, Jorkasky DJ, Ilson BE (1990) Dose-proportional stereoselectivity of carvedilol pharmacokinetics. Clin Pharmacol Ther 49: 126
7. 7. Bartsch W, Sponer G, Strein K, Muller-Beckmann B, Kling L, Bohm E, Martin U, Borbe HO (1990) Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 38: S104-S107
8. 8. Bianchetti G, Graziani G, Brancaccio D, Morganti A, Leonetti G, Manfrin M, Sega R, Gomeni R, Ponticelli C, Morselli PL (1976) Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1: 373-384
9. 9. Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ (1974) Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther 16: 761-769
10. 10. Kramer BK, Ress KM, Erley CM, Risler T (1992) Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. Eur J Clin Pharmacol 43: 85-88
11. 11. Deetjen A, Heidland A, Pangerl A, Meyer-Sabelled W, Schaefer RM (1995) Antihypertensive treatment with vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients. Clin Nephrol 43: 47-52
12. 12. Hakusui H, Fujimaki M (1988) Pharmacokinetics of carvedilol in hypertensive patients with renal failure. Drugs 36 [Suppl 6]: 144-147
13. 13. Masumura H, Miki S, Kaifu Y, Kitajima W, Abe Y (1992) Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. J Cardiovasc Pharmacol 19 [Suppl 1]: S102-S107
14. 14. Morgan TO, Anderson A, Cripps J, Adam W (1990) The use of carvedilol in elderly hypertensive patients. Eur J Clin Pharmacol 38: S129-S133
15. 15. Jordo L, Attman P, Aurell M, Hohansson L, Johnsson G, et al (1980) Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet 5: 169-180
16. 16. Walle T, Walle UK, Cowart TD, Conradi EC (1989) Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 46: 257-263
17. 17. Zhou HH, Wood AJJ (1995) Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57: 518-524